Exam 2 Week 7: Blood Pressure, Heart, and Coagulation Pharmacology

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/40

flashcard set

Earn XP

Description and Tags

Vocabulary flashcards covering cardiovascular pharmacology, including antihypertensives, heart failure drugs, antiarrhythmics, lipid-lowering agents, and anticoagulants.

41 Terms

1
New cards

Hydrochlorothiazide

Thiazide diuretic used as a first-line option for hypertension and mild edema; requires morning dosing and monitoring of blood pressure, sodium, potassium, glucose, uric acid, and dehydration, with muscle weakness or cramps signaling potential hypokalemia.

2
New cards

Captopril

Angiotensin-converting enzyme (ACE) inhibitor for hypertension and heart failure that decreases angiotensin II and aldosterone; adverse effects include hyperkalemia, dry cough, and life-threatening angioedema caused by bradykinin accumulation.

3
New cards

Losartan

Angiotensin receptor blocker (ARB) used for hypertension, heart failure, and renal protection in selected patients; blocks angiotensin receptors without causing significant bradykinin accumulation, making cough less common than with ACE inhibitors.

4
New cards

Aliskiren

Direct renin inhibitor used for hypertension; must not be combined with ACE inhibitors or ARBs in patients with diabetes due to heightened risks of hyperkalemia, renal impairment, and angioedema from dual RAAS blockade.

5
New cards

Nifedipine

Dihydropyridine calcium-channel blocker that relaxes vascular smooth muscle for hypertension and angina; extended-release forms must not be crushed, and immediate-release formulations should be avoided in hypertensive emergencies due to severe hypotension and reflex tachycardia.

6
New cards

Verapamil

Non-dihydropyridine calcium-channel blocker for hypertension, angina, and supraventricular tachycardias; slows atrioventricular (AV) conduction, increasing the risk of bradycardia and heart block when combined with other rate-slowing agents, and commonly causes constipation.

7
New cards

Diltiazem

Non-dihydropyridine calcium-channel blocker indicated for blood pressure control, angina, and atrial rate control; functions by slowing AV-node conduction and relaxing arteries, requiring monitoring for bradycardia, heart block, and peripheral edema.

8
New cards

Metoprolol

Beta-1 selective adrenergic antagonist used for hypertension, angina, heart failure, and rate control; requires caution in asthma because beta-1 selectivity is dose-dependent and higher doses can block pulmonary beta-2 receptors.

9
New cards

Propranolol

Nonselective beta blocker prescribed for blood pressure, angina, dysrhythmias, essential tremor, and migraine prophylaxis; strictly avoided in bronchial asthma or bronchospasm due to bronchoconstrictive beta-2 blockade.

10
New cards

Carvedilol

Beta-adrenergic blocker taken with food that requires monitoring of heart rate, blood pressure, orthostasis, weight, and glucose; can induce bronchospasm via beta-2 blockade and mask symptoms of hypoglycemia by suppressing tachycardia.

11
New cards

Nitroprusside

Rapid IV arterial and venous vasodilator for hypertensive emergencies; requires continuous blood pressure monitoring, light protection, and assessment for cyanide/thiocyanate toxicity evidenced by confusion, severe lactic acidosis, or collapse.

12
New cards

Eplerenone

Selective aldosterone antagonist for hypertension and heart failure that prevents potassium loss with fewer hormonal side effects than spironolactone; requires monitoring for hyperkalemia and avoidance of strong CYP3A4 inhibitors.

13
New cards

Epinephrine

Catecholamine agonist for anaphylaxis, cardiac arrest, and severe bronchospasm; stimulates alpha receptors to elevate blood pressure, beta-1 receptors to stimulate the heart, and beta-2 receptors to open bronchi, with IM injection into the outer thigh as the first-line route in anaphylaxis.

14
New cards

Dobutamine

Intravenous beta-1 adrenergic agonist inotrope indicated for short-term hemodynamic support in severe heart failure and low cardiac output states.

15
New cards

Sacubitril / Valsartan

Angiotensin receptor-neprilysin inhibitor (ARNI) indicated for chronic heart failure with reduced ejection fraction (HFrEF); must never be administered within 36 hours of an ACE inhibitor due to severe angioedema risk from cumulative bradykinin elevation.

16
New cards

Digoxin

Cardiac glycoside used for heart failure symptoms and ventricular rate control in atrial fibrillation; requires assessment of an apical pulse for 1 full minute (holding for HR < 60 in adults), with hypokalemia potentiating toxicity (anorexia, nausea, vision changes, dysrhythmias), which is reversed by digoxin immune Fab.

17
New cards

Furosemide

Loop diuretic for heart failure and edema that produces rapid, potent sodium and fluid excretion; requires surveillance for dehydration, hypokalemia, and ototoxicity during high-dose or rapid IV administration.

18
New cards

Spironolactone

Potassium-sparing aldosterone receptor antagonist for heart failure, hypertension, and ascites; conserves potassium and can cause hyperkalemia as well as antiandrogenic endocrine effects like gynecomastia.

19
New cards

Mannitol

Intravenous osmotic diuretic used to reduce elevated intracranial or intraocular pressure by drawing water into the intravascular space; must be stopped if pulmonary edema or crackles occur, and requires inspection for crystals and the use of an in-line filter.

20
New cards

Nitroglycerin

Nitrate for acute angina that dilates coronary vessels and peripheral veins; administered sublingually with instructions to call 911 if chest pain persists 5 minutes after the first dose, and absolutely contraindicated with PDE-5 inhibitors due to profound hypotension.

21
New cards

Ranolazine

Antianginal agent that selectively reduces the late sodium current to manage chronic angina without significantly altering heart rate or blood pressure; prolongs the QT interval and is not used for terminating acute anginal episodes.

22
New cards

Atorvastatin

HMG-CoA reductase inhibitor (statin) that lowers LDL cholesterol by inhibiting hepatic cholesterol synthesis; requires monitoring for liver dysfunction and rhabdomyolysis, which is characterized by muscle pain, weakness, or dark urine.

23
New cards

Ezetimibe

Cholesterol-absorption inhibitor that selectively decreases LDL cholesterol by blocking the uptake of dietary and biliary cholesterol at the brush border of the small intestine.

24
New cards

Colesevelam

Bile-acid sequestrant that binds bile acids in the intestine to lower LDL cholesterol and blood glucose; adverse effects include constipation, bloating, intestinal obstruction, and increased triglyceride levels.

25
New cards

Alirocumab

Injectable PCSK9 monoclonal antibody that drastically lowers circulating LDL levels by preventing PCSK9 from degrading LDL receptors, used primarily in familial hypercholesterolemia or very high-risk cardiovascular disease.

26
New cards

Quinidine

Class Ia antiarrhythmic that blocks sodium channels and delays repolarization; classic adverse manifestations include cinchonism (tinnitus, diarrhea) and QT interval prolongation that can lead to torsades de pointes.

27
New cards

Lidocaine

Class Ib antiarrhythmic and local anesthetic utilized for ventricular arrhythmias; central nervous system and cardiac toxicities include circumoral paresthesias, metallic taste, tinnitus, confusion, seizures, and dysrhythmias.

28
New cards

Propafenone

Class Ic antiarrhythmic used for selected atrial dysrhythmias; causes profound cardiac conduction slowing that carries proarrhythmic risk, making it contraindicated in significant structural heart disease.

29
New cards

Flecainide

Class Ic sodium-channel blocker for selected atrial dysrhythmias; excessive conduction slowing manifests as QRS widening or emergent ventricular arrhythmias, signaling serious toxicity and proarrhythmia.

30
New cards

Amiodarone

Iodine-rich Class III antiarrhythmic with an extensive half-life used for serious atrial and ventricular dysrhythmias; accumulates in tissues and requires monitoring for pulmonary toxicity (cough, dyspnea), thyroid disruption, hepatotoxicity, and corneal/skin changes.

31
New cards

Adenosine

Ultra-short-acting AV-nodal blocking agent with a half-life of seconds used to convert paroxysmal supraventricular tachycardia (PSVT); administered via rapid IV push with an immediate saline flush, often provoking brief flushing, dyspnea, chest tightness, or transient asystole.

32
New cards

Atropine

Anticholinergic agent indicated for symptomatic bradycardia and cholinergic poisoning; competitively inhibits acetylcholine at muscarinic receptors to increase sinus node firing.

33
New cards

Heparin

Unfractionated anticoagulant that accelerates antithrombin activity; monitored using aPTT or anti-Xa levels, reversed with protamine sulfate, and carries a risk of immune-mediated heparin-induced thrombocytopenia (HIT).

34
New cards

Enoxaparin

Low-molecular-weight heparin administered subcutaneously in the abdomen without expelling the air bubble or rubbing the site; used for thromboprophylaxis and treatment, posing a risk of neuraxial hematoma and only partial reversibility by protamine.

35
New cards

Fondaparinux

Synthetic indirect factor Xa inhibitor indicated for DVT and PE prophylaxis and treatment; lacks a specific routine reversal agent, is contraindicated in severe renal impairment, and carries a major warning for spinal/epidural hematomas.

36
New cards

Warfarin

Oral vitamin K antagonist used for long-term anticoagulation; requires INR monitoring, dietary vitamin K consistency, and avoidance during pregnancy, with reversal achieved via vitamin K or 4-factor prothrombin complex concentrate (PCC).

37
New cards

Dabigatran

Oral direct thrombin inhibitor used for DVT/PE management and stroke prevention in nonvalvular atrial fibrillation; must be retained in its original moisture-resistant packaging and is specifically reversed by idarucizumab.

38
New cards

Argatroban

Intravenous direct thrombin inhibitor utilized primarily as an alternative anticoagulant in heparin-induced thrombocytopenia (HIT); metabolized by the liver and known to inherently elevate the INR, which complicates warfarin transitions.

39
New cards

Rivaroxaban

Oral direct factor Xa inhibitor for atrial fibrillation, DVT, and PE that does not mandate routine INR monitoring; critical signs of hemorrhagic toxicity include hematuria, melena, hematemesis, or sudden severe headache.

40
New cards

Clopidogrel

Oral P2Y12 platelet adenosine diphosphate (ADP) receptor antagonist that prevents platelet activation and prevents stent thrombosis; premature cessation significantly increases the risk of acute coronary stent occlusion.

41
New cards

Alteplase (tPA)

Fibrinolytic enzyme that catalyzes the conversion of plasminogen to plasmin to lyse pathological intravascular thrombi; carries a high risk of life-threatening bleeding, particularly intracranial hemorrhage signaled by acute neurological decline or sudden severe headache.